Literature DB >> 16862252

Neuropsychiatric phenomena associated with movement disorders.

Joshua L Roffman1, Todd Eisenberg, Theodore A Stern.   

Abstract

Entities:  

Year:  2006        PMID： 16862252      PMCID： PMC1510909          DOI： 10.4088/pcc.v08n0106

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN： 1523-5998


× No keyword cloud information.
  14 in total

Review 1.  Dementia in Parkinson's disease.

Authors:  A D Korczyn
Journal:  J Neurol       Date:  2001-09       Impact factor: 4.849

Review 2.  Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma.

Authors:  S Kuzuhara
Journal:  J Neurol       Date:  2001-09       Impact factor: 4.849

3.  Effectiveness of ECT in patients with parkinsonism.

Authors:  C Moellentine; T Rummans; J E Ahlskog; W S Harmsen; V J Suman; M K O'Connor; J L Black; T Pileggi
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1998       Impact factor: 2.198

4.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 5.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  L Marsh
Journal:  Psychosomatics       Date:  2000 Jan-Feb       Impact factor: 2.386

6.  Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease.

Authors: 
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

Review 7.  Atypical antipsychotics in Parkinson-sensitive populations.

Authors:  Joseph H Friedman; Hubert H Fernandez
Journal:  J Geriatr Psychiatry Neurol       Date:  2002       Impact factor: 2.680

Review 8.  Progressive supranuclear palsy: where are we now?

Authors:  David J Burn; Andrew J Lees
Journal:  Lancet Neurol       Date:  2002-10       Impact factor: 44.182

Review 9.  Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease.

Authors:  David J Burn
Journal:  Mov Disord       Date:  2002-05       Impact factor: 10.338

10.  Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.

Authors:  Jorge L Juncos; Vicki J Roberts; Marian L Evatt; Rita D Jewart; Colleen D Wood; Larry S Potter; Hann-Chang Jou; Paul P Yeung
Journal:  Mov Disord       Date:  2004-01       Impact factor: 10.338
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.